X0306 4 2015-05-04 0 0001311596 Tobira Therapeutics, Inc. TBRA 0001279800 WEBER ECKARD C/O TOBIRA THERAPEUTICS, INC. 701 GATEWAY BOUEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2015-05-04 4 A 0 243726 0.00 A 243726 I By Eckard Weber, M.D., Trustee of the Eckard Weber Living Trust UTA dated November 20, 2007 Common Stock 2015-05-04 4 A 0 36187 0.00 A 36187 I By Domain Associates, L.L.C. Common Stock 2015-05-04 4 A 0 3553322 0.00 A 3553322 I By Domain Partners VII, L.P. Common Stock 2015-05-04 4 A 0 47613 0.00 A 47613 I By DP VII Associates, L.P. Stock Options (right to buy) 2.96 2015-05-04 4 A 0 4332 0.00 A 2019-06-22 Common Stock 4332 4332 D Reporting Person received 243,726 of such shares in exchange for shares of Tobira Therapeutics, Inc. ("Tobira") common stock in connection with the merger of Tobira into Issuer (the "Merger"). Pursuant to the terms of the Merger agreement each share of Tobira common stock will automatically be converted into the right to receive 1.43 shares of Issuer common stock. Shares held by the Reporting Person as Trustee of the Eckard Weber Living Trust UTA dated November 20, 2007 (the "Weber Trust"). The Reporting Person is a trustee and beneficiary of the Weber Trust, and may be deemed to share voting and dispositive power with regard to the reported shares held by the Weber Trust. The Reporting Person is a Managing Member of (i) One Palmer Square Associates VII, LLC, which is the sole general partner of Domain Partners VII, L.P. and DP VII Associates, L.P., and (ii) Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Reporting Person received 3,275,545 of such shares in exchange for shares of Tobira Therapeutics, Inc. ("Tobira") common stock in connection with the merger of Tobira into Issuer (the "Merger"). Pursuant to the terms of the Merger agreement each share of Tobira common stock will automatically be converted into the right to receive 1.43 shares of Issuer common stock. Reporting Person purchased 277,777 of such shares from Issuer pursuant to a Purchase Agreement. Reporting Person received such stock option in exchange for a stock option to purchase Tobira Therapeutics, Inc. ("Tobira") common stock in connection with the merger of Tobira into Issuer (the "Merger"). Pursuant to the terms of the Merger agreement each Tobira stock option assumed will be determined by multiplying the number of options by the exchange ratio of 1.43 and rounding down to the nearest whole number. The shares are fully vested and exercisable at any time. /s/ Christopher Reilly, attorney-in-fact 2015-05-06